Glycogen storage disease type I is a rare inherited condition that disrupts the body’s ability to maintain stable blood sugar levels, particularly during fasting. First identified nearly a century ago, this disorder affects how the liver and kidneys process stored sugar, leading to serious metabolic challenges that require careful lifelong management.

Understanding Glycogen Storage Disease Type I

Glycogen storage disease type I, also known as Von Gierke disease, is a genetic disorder that prevents the body from properly breaking down stored glycogen (a complex sugar stored in the body) into glucose. This condition was first described by Dr. Edgar Von Gierke in 1929, and it remains one of the most significant metabolic disorders affecting children and adults.^[1]

The disease occurs because of problems with specific enzymes that normally help convert glycogen into glucose, which is the body’s main source of energy. When these enzymes don’t work properly, glycogen accumulates primarily in the liver and kidneys, causing these organs to become enlarged and leading to dangerously low blood sugar levels during periods when a person hasn’t eaten.^[2]

Epidemiology

Glycogen storage disease type I is considered a rare condition. The overall incidence is approximately 1 in 100,000 individuals worldwide. This means that in a city of one million people, only about ten individuals would be expected to have this condition.^[2][4]

Among the different types of glycogen storage disease, type I is actually the most common form. Within type I itself, there are two main subtypes: type Ia accounts for about 80 percent of all cases, while type Ib makes up the remaining 20 percent. Both subtypes affect males and females equally, as the condition is inherited in what doctors call an autosomal recessive pattern, meaning it is not linked to sex chromosomes.^[2]

Causes

Glycogen storage disease type I is caused by mutations in specific genes that are responsible for producing enzymes needed to break down glycogen. These mutations are inherited from both parents, who are typically healthy carriers of the gene change. When both parents pass the altered gene to their child, the child develops the condition.^[1]

Type Ia results from mutations in the G6PC1 gene, which normally produces an enzyme called glucose-6-phosphatase. This enzyme plays a crucial role in the final step of converting stored glycogen into glucose that can enter the bloodstream. When this enzyme is deficient or absent, the conversion cannot happen efficiently.^[2]

Type Ib is caused by mutations in the SLC37A4 gene, which produces a transport protein called glucose-6-phosphate translocase. This protein moves glucose-6-phosphate molecules to the proper location in cells where they can be converted to glucose. Even though the glucose-6-phosphatase enzyme itself may be present in type Ib, the glucose-6-phosphate molecules cannot reach it, resulting in similar metabolic problems.^[1]

The inheritance pattern is autosomal recessive, meaning both copies of the gene in each cell must have mutations for the disease to develop. Parents who each carry one mutated copy typically do not show symptoms themselves, but they have a 25 percent chance with each pregnancy of having a child with the condition.^[2]

Risk Factors

The primary risk factor for glycogen storage disease type I is having parents who both carry a mutation in either the G6PC1 or SLC37A4 gene. Because this is a genetic condition, family history is the most significant risk factor. If parents have already had one child with the condition, they have a one in four chance of having another affected child with each subsequent pregnancy.^[4]

Certain ethnic or geographic populations may have slightly higher carrier rates for specific mutations, though glycogen storage disease type I can occur in any ethnic group. Couples with a family history of metabolic disorders or unexplained infant deaths may be at higher risk of being carriers.^[4]

Unlike many other diseases, there are no lifestyle factors, environmental exposures, or behavioral choices that increase the risk of developing this condition. It is purely genetic and present from birth, though symptoms may not become apparent immediately after delivery.^[1]

Symptoms

The symptoms of glycogen storage disease type I typically begin to appear around three to four months of age. This timing corresponds to when babies start sleeping through the night and going longer periods between feedings, which reveals the body’s inability to maintain stable blood sugar levels during fasting.^[1][2]

The most serious early symptom is severe low blood sugar, or hypoglycemia, which occurs when babies go several hours without eating. Low blood sugar can cause seizures, which may be one of the first signs that alerts parents and doctors to a problem. Other symptoms of low blood sugar include excessive sweating, shakiness, irritability, and extreme hunger.^[2]

As affected infants grow, they often develop a characteristic appearance. Their abdomen may appear swollen or protruding due to an enlarged liver. Their arms and legs tend to remain thin, and they may have poor growth and be shorter than expected for their age. The face may develop a round, doll-like appearance.^[2]

Other common symptoms include chronic diarrhea and deposits of cholesterol under the skin, appearing as small yellowish bumps called xanthomas. Children may also experience a buildup of lactic acid in the body, leading to fatigue and rapid breathing, as well as high levels of uric acid in the blood, which can cause joint pain.^[2]

As children with glycogen storage disease type I reach adolescence and adulthood, additional complications may develop. Puberty may be delayed. Young adults may develop thinning of the bones, a condition called osteoporosis, as well as a form of arthritis caused by uric acid crystals accumulating in the joints, known as gout. The kidneys may become damaged over time, leading to kidney disease and high blood pressure. Females may develop abnormal ovaries with multiple cysts.^[2]

In teenage and adult years, there is also a risk of developing non-cancerous tumors in the liver called adenomas. While these tumors are usually benign, they occasionally have the potential to become cancerous, requiring regular monitoring throughout life.^[2]

Prevention

Because glycogen storage disease type I is an inherited genetic condition, it cannot be prevented in the traditional sense through lifestyle changes, vaccinations, or environmental modifications. However, there are steps that families can take to understand their risk and make informed decisions about family planning.^[4]

Genetic testing and counseling are available for couples who have a family history of glycogen storage disease type I or who have already had one affected child. Carrier testing can identify whether parents carry mutations in the G6PC1 or SLC37A4 genes, which can help them understand the likelihood of having an affected child. If both parents are carriers, genetic counselors can discuss options including prenatal testing during pregnancy.^[2]

Prenatal diagnostic testing is possible through procedures such as amniocentesis or chorionic villus sampling, which can determine whether a developing baby has inherited the condition. This information allows families to prepare for the special care their child will need from birth and ensures that appropriate medical teams are ready at delivery.^[2]

For families already caring for a child with glycogen storage disease type I, prevention focuses on avoiding the serious complications of the disease. This means preventing episodes of severe low blood sugar through careful dietary management, monitoring for liver tumors through regular imaging, and watching for signs of kidney problems. Early identification and management of these complications can prevent more serious outcomes.^[8]

Pathophysiology

To understand what goes wrong in glycogen storage disease type I, it helps to know how the body normally manages energy. When we eat, carbohydrates from food are broken down into glucose, which provides immediate energy to cells. The body stores excess glucose in the liver and muscles as glycogen, a complex branching molecule made of many glucose units linked together. During periods between meals or overnight when we’re not eating, the body breaks down stored glycogen back into glucose to maintain stable blood sugar levels.^[4]

The final critical step in releasing glucose from the liver into the bloodstream requires the enzyme glucose-6-phosphatase. This enzyme converts glucose-6-phosphate, which cannot leave liver cells, into free glucose, which can enter the bloodstream and travel to cells throughout the body. In glycogen storage disease type Ia, this enzyme is missing or doesn’t work properly. In type Ib, the transporter that moves glucose-6-phosphate to where the enzyme can act on it is defective.^[1]

When glucose-6-phosphate cannot be converted to glucose and released from the liver, several problems occur simultaneously. First, blood sugar levels drop dangerously low during fasting because the liver cannot release glucose into the bloodstream. This causes the symptoms of hypoglycemia, including confusion, shakiness, and in severe cases, seizures.^[1]

Second, because glucose-6-phosphate accumulates inside liver cells but cannot be converted to glucose, it gets diverted into other metabolic pathways. Some is converted back into glycogen, causing massive glycogen accumulation in the liver. This makes the liver become significantly enlarged, sometimes growing to several times its normal size. The stored glycogen also accumulates in the kidneys, causing them to enlarge as well.^[1]

The blocked glucose-6-phosphate also gets converted into fats, leading to abnormally high levels of cholesterol and triglycerides in the blood, a condition called hyperlipidemia. Additionally, it enters a metabolic pathway that produces lactic acid, resulting in a buildup of acid in the blood known as lactic acidosis. High lactic acid levels can cause rapid breathing, nausea, and fatigue.^[1]

The metabolic disruption also affects uric acid levels. Uric acid, a waste product that is normally filtered by the kidneys, builds up to abnormally high levels in the blood. Over time, uric acid crystals can deposit in joints, causing gout, and in the kidneys, contributing to kidney damage and the formation of kidney stones.^[2]

In type Ib specifically, the defective transporter affects not just liver metabolism but also the function of neutrophils, a type of white blood cell critical for fighting infections. Neutrophils rely on the same transport system to maintain their energy metabolism and normal function. When this transporter doesn’t work, neutrophil production in the bone marrow is impaired, and the neutrophils that are produced don’t function properly. This leads to chronic neutropenia (low neutrophil counts) and increased susceptibility to bacterial infections.^[1]

Over many years, the chronic metabolic stress and glycogen accumulation can lead to additional complications. The liver may develop non-cancerous tumors called adenomas, likely due to the constant metabolic stress on liver cells. The kidneys may develop progressive damage, potentially leading to kidney failure. Bones may become thin and weak due to metabolic imbalances affecting calcium and phosphorus metabolism.^[2]